NYRADA INC. (ASX:NYR) 6 Widening the Question In the 2026 financial year, we also widened the question. Calcium overload is not just a cardiac, neurological, or renal problem. It is a cellular problem, and a mechanism that matters in one organ under stress will often matter elsewhere. That logic led us into oncology. Preclinical work demonstrated clear anti-tumour activity in a model of liver cancer, both alone and combined with the widely used chemotherapy doxorubicin. The combination produced the greatest reduction in tumour volume while remaining well tolerated. A separate parallel pilot study explored Xolatryp’s potential to shield the heart from the cardiotoxicity that limits anthracycline chemotherapies. This opens another therapeutic front for our TRPC platform. Protecting Innovation Work of this kind creates lasting value only if it can be defended. During FY2026 our composition of matter patent application was published, our Xolatryp® trademark was granted, and the Company received a Notice of Allowance from the United States Patent Office. Subject to payment of the issue fee, the resulting grant will provide protection over Xolatryp’s chemical structure in the world’s largest pharmaceutical market for a twenty-year term from the September 2024 priority date. A Pathway to the United States Our ambitions for Xolatryp are global. Late in the financial year the Company began preparing an Investigational New Drug (IND) application for the US Food and Drug Administration with submission targeted before the end of the 2026 calendar year. Together with our collaboration with the US military research community, this lays the groundwork for development on both sides of the Pacific. Financial Strength and Discipline Ambition without discipline is merely appetite. Nyrada entered FY2026 in a materially stronger financial position than a year earlier, having raised AU$8.25 million (before costs) in the financial year to fully fund the Phase IIa trial, explore drug manufacture, and finance further research into the opportunities for Xolatryp. The Company maintained its customary financial discipline throughout the year, received an R&D tax rebate of AU$2.45 million in respect of its FY2025 claim, and benefited from proceeds received on the exercise of options. As at 30 June 2026, Nyrada held a cash position of $8.38 million, leaving the Company well positioned to prosecute its clinical and preclinical programs. Our full-year financial results are set out in the Directors’ Report and financial statements that follow. “Xolatryp completed its first-in-human Phase I trial in 48 healthy volunteers with no serious adverse events or dose-limiting toxicities, and with a predictable, welltolerated pharmacokinetic profile.”
RkJQdWJsaXNoZXIy MjE2NDg3